Key result
DOACs are linked to ~34% lower intracerebral hemorrhage rates compared to VKAs.
Why the study?
The incidence and time trends of intracerebral hemorrhage associated with oral anticoagulation in Spain had not been previously assessed despite increasing oral anticoagulant use.
Observational (n=1,919)
No
Answers are grounded in this paper and cite their sources.
BACKGROUND: Intracerebral hemorrhage (ICH) is 7- to 10-fold higher in anticoagulated patients. Given the more extended use of oral anticoagulants, an increase in the prevalence of ICH associated with oral anticoagulation (ICH-OAC) could be expected. However, there is no previous study that assesses the time trends of ICH-OAC in Spain. METHODS: We conducted a combined data analysis after creating a joint database of the 3 most important epidemiological studies on ICH-OAC of our country: the EPICES study (2008-2009), the TAC Registry (TR) study (2012-2013) and the TAC Registry 2 (TR2) study (2015). We finally included 65, 235, and 366 patients from the EPICES, TR, and TR2 studies, respectively. RESULTS: We have observed a 3.73-fold increase in the crude annual incidence of ICH-OAC throughout the period of study, with proportion of ICH-OAC out of total ICH increasing from 8.4% in 2008 to 18.2% in 2015. Age, dyslipidemia, and prior antiplatelet treatment increased during the study, but we found no statistically significant differences in other risk factors for ICH-OAC. CONCLUSIONS: The incidence of ICH-OAC is increasing in our country. It might at least be partly explained by aging of the population, with mean age at presentation being higher in the last years.
No takes yet. Share an insight, caveat, or question.
Quintas et al. (2020) conducted an observational in Intracerebral hemorrhage (ICH) and Oral Anticoagulant Use (n=1,919). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKA) was evaluated on Annual incidence of intracerebral hemorrhage per 10,000 patients on oral anticoagulants (IRR 0.66, 95% CI 0.47-0.91, p=0.011). Direct oral anticoagulants were associated with a 34.2% lower incidence rate of intracerebral hemorrhage compared to vitamin K antagonists (IRR 0.66).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: